Bristol-Myers Squibb (NYSE:BMY) Stock Position Decreased by Seizert Capital Partners LLC

Seizert Capital Partners LLC lessened its holdings in shares of Bristol-Myers Squibb (NYSE:BMY) by 1.7% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 704,735 shares of the biopharmaceutical company’s stock after selling 12,519 shares during the quarter. Bristol-Myers Squibb makes up approximately 1.8% of Seizert Capital Partners LLC’s portfolio, making the stock its 24th largest holding. Seizert Capital Partners LLC’s holdings in Bristol-Myers Squibb were worth $39,860,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Swedbank AB raised its stake in shares of Bristol-Myers Squibb by 0.9% in the 3rd quarter. Swedbank AB now owns 3,139,552 shares of the biopharmaceutical company’s stock valued at $162,440,000 after acquiring an additional 28,427 shares in the last quarter. Pettinga Financial Advisors LLC grew its holdings in Bristol-Myers Squibb by 8.7% during the third quarter. Pettinga Financial Advisors LLC now owns 11,108 shares of the biopharmaceutical company’s stock valued at $575,000 after purchasing an additional 886 shares during the last quarter. Focus Financial Network Inc. acquired a new stake in shares of Bristol-Myers Squibb in the third quarter worth $202,000. Forum Financial Management LP boosted its holdings in shares of Bristol-Myers Squibb by 14.5% during the 3rd quarter. Forum Financial Management LP now owns 11,422 shares of the biopharmaceutical company’s stock worth $591,000 after buying an additional 1,447 shares during the period. Finally, PDS Planning Inc grew its stake in Bristol-Myers Squibb by 14.5% in the 3rd quarter. PDS Planning Inc now owns 5,514 shares of the biopharmaceutical company’s stock valued at $285,000 after buying an additional 699 shares during the last quarter. 76.41% of the stock is currently owned by institutional investors and hedge funds.

Bristol-Myers Squibb Stock Performance

Shares of NYSE:BMY opened at $59.52 on Wednesday. The stock has a market capitalization of $120.77 billion, a price-to-earnings ratio of -13.46, a price-to-earnings-growth ratio of 2.07 and a beta of 0.45. The business’s fifty day moving average price is $57.23 and its two-hundred day moving average price is $54.93. Bristol-Myers Squibb has a fifty-two week low of $39.35 and a fifty-two week high of $61.10. The company has a debt-to-equity ratio of 2.90, a current ratio of 1.25 and a quick ratio of 1.15.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, February 6th. The biopharmaceutical company reported $1.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.47 by $0.20. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. As a group, analysts predict that Bristol-Myers Squibb will post 6.74 EPS for the current fiscal year.

Bristol-Myers Squibb Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, May 1st. Shareholders of record on Friday, April 4th will be given a $0.62 dividend. The ex-dividend date is Friday, April 4th. This represents a $2.48 annualized dividend and a yield of 4.17%. Bristol-Myers Squibb’s payout ratio is -56.11%.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Daiwa America upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “strong-buy” rating in a report on Wednesday, November 13th. Citigroup increased their target price on Bristol-Myers Squibb from $60.00 to $65.00 and gave the company a “neutral” rating in a research note on Tuesday, January 28th. Wells Fargo & Company lifted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the stock an “equal weight” rating in a research report on Friday, February 7th. Jefferies Financial Group raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating and increased their price objective for the company from $63.00 to $70.00 in a research report on Monday, December 16th. Finally, Morgan Stanley upped their target price on shares of Bristol-Myers Squibb from $36.00 to $39.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating, four have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus target price of $57.86.

Insiders Place Their Bets

In other Bristol-Myers Squibb news, EVP Samit Hirawat purchased 1,823 shares of the business’s stock in a transaction that occurred on Friday, February 14th. The stock was acquired at an average cost of $54.84 per share, with a total value of $99,973.32. Following the completion of the acquisition, the executive vice president now directly owns 63,932 shares of the company’s stock, valued at $3,506,030.88. This represents a 2.94 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 0.09% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.